Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2200-2205

  Akagi, Satoshi ^a,b   Nakamura, Kazufumi ^b   Miyaji, Katsumasa ^a   Ogawa, Aiko ^b   Kusano, Kengo Fukushima ^b   Ito, Hiroshi ^b   Matsubara, Hiromi ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Epoprostenol; Idiopathic pulmonary arterial hypertension; Prostacyclin

Indexed keywords

PROSTACYCLIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEMALE; FLUSHING; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; JAW DISEASE; JAW PAIN; KIDNEY DYSFUNCTION; LEG PAIN; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; RASH; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EPOPROSTENOL; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MAXIMUM TOLERATED DOSE; PULMONARY ARTERY; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 77958036618     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0190     Document Type: Article

References (21)

1. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research "Work in progress". Circulation 2000; 102: 2781-2791.
2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-1544.
3. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: The need for multiple hits. Circulation 2005; 111: 534-538.
4. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
5. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
6. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987; 107: 216-223.
7. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
8. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
9. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
10. Sakuma M, Demachi J, Nawata J, Suzuki J, Takahashi T, Shirato K. Long-term epoprostenol therapy in pulmonary artery hypertension. Circ J 2009; 73: 523-529.
11. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
12. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-1187.
13. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
14. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
15. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(Suppl S): 5S-12S.
16. Akagi S, Matsubara H, Ogawa A, Kawai Y, Hisamatsu K, Miyaji K, et al. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J 2007; 71: 559-564.
17. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1: 1046-1047.
18. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
19. Sakuma M, Demachi J, Nawata J, Suzuki J, Takahashi T, Matsubara H, et al. Epoprostenol infusion therapy changes angiographic findings of pulmonary arteries in patients with idiopathic pulmonary arterial hypertension. Circ J 2008; 72: 1147-1151.
20. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000; 102: 3130-3136.
21. Akagi S, Matsubara H, Miyaji K, Ikeda E, Dan K, Tokunaga N, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72: 1142-1146.